Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 14/20 | 0.39 |
| ▸ | F3 | P13726 | 14/20 | 0.39 |
| ▸ | F10 | P00742 | 9/20 | 0.39 |
| ▸ | F2 | P00734 | 8/20 | 0.39 |
| ▸ | F11 | P03951 | 6/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2916733 | 0.96 | F7 (0.36) | F7F3F10F2F11 | |
| SCHEMBL2908389 | 0.94 | F7 (0.35) | F7F3F10F2F11 | |
| SCHEMBL13613589 | 0.93 | F7 (0.39) | F7F3F10F2F11 | |
| SCHEMBL2915392 | 0.93 | F7 (0.44) | F7F3F10F2F11 | |
| SCHEMBL2912583 | 0.92 | F7 (0.40) | F7F3F10F2F11 | |
| SCHEMBL4332034 | 0.91 | F7 (0.37) | F7F3F10F2F11 | |
| SCHEMBL2916691 | 0.90 | F7 (0.35) | F7F3F10F2F11 | |
| SCHEMBL2846745 | 0.88 | F7 (0.44) | F7F3F10F2F11 | |
| SCHEMBL13613537 | 0.88 | F7 (0.43) | F7F3F10F2F11 | |
| SCHEMBL5003230 | 0.88 | F7 (0.39) | F7F3F10F2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622585-B2 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622585-B2 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | TFPI, SERPINC1, SERPINE1 | F7 35/4885F3 20/4885F10 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.